CubeSat launch platform by Vector House Biosciences will increase house biotech
by Brad Bartz
Los Angeles CA (SPX) Nov 22, 2023
In a brand new collaboration, Vector House Biosciences, Inc. has joined forces with Oracle and NVIDIA to introduce a novel small satellite tv for pc launch platform for CubeSat and NanoSats, which were particularly designed to cater to the wants of the biotechnology and pharmaceutical sectors.
This modern platform represents a mix of a number of cutting-edge applied sciences, together with a biosciences lab, a CubeSat lab, and a language modeling/AI lab. It embodies a mix of extremely focused and enormous organic language modeling (LLMs), generative AI, protein sequence matching, vector databases, and superior visualizations.
The first purpose of this platform is to facilitate the event of countermeasures in opposition to ailments related to the stressors ensuing from human spaceflight. These countermeasures aren’t solely essential for safeguarding people in house but in addition maintain immense potential as new types of precision drugs for the broader inhabitants.
As soon as in orbit knowledge collected from the CubeSat can be transmitted again to Earth, by way of floor stations operated in collaboration with Microsoft Azure House. This knowledge, enriched with present biomedical data, undergoes preprocessing for language modeling. Subsequently, characteristic vectors extracted from the educated fashions are employed to assemble real-time hidden relationship networks. These networks intricately map the connections between genes, proteins, ailments, drug compounds, and different biochemical entities.
The information emanating from CubeSats in house is uniquely invaluable. It has the potential to unlock new discoveries in drug discovery, improvement, and design. This knowledge isn’t just about novel drug creation; it additionally performs a important position in drug repurposing, a key space of discovery within the pharmaceutical business.
A latest instance underscoring the significance of drug repurposing is Novo Nordisk’s Wegovy (semaglutide), a weight reduction drug initially developed for diabetes administration. This drug has now been proven to scale back the incidence of coronary heart assaults, strokes, or demise from coronary heart illness by 20%, along with serving to sufferers lose a median of 15% of their physique weight.
Kasian Franks, the founder and CEO of Vector House Biosciences, highlights the broader implications of their work. “With out understanding the right way to shield and restore the human physique throughout spaceflight, we merely will not be establishing lunar bases or going to Mars anytime quickly. Nevertheless, if we deal with creating options on this space now, we will develop and repurpose new therapeutic purposes in precision drugs that profit all mankind, right this moment. That is the main focus of Vector House Biosciences.”
Associated Hyperlinks
Vector House Biosciences
House Medication Expertise and Techniques